News PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Delayed Australian S.E. Other stock markets 08:06:42 2024-04-17 pm EDT			5-day change	1st Jan Change
0.094 ^AUD	+1.08%		-6.00%	-14.55%

Apr. 10	PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	MT
Mar. 18	PYC Therapeutics Raises AU$40 Million via Entitlement Offer	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	Apr. 10	MT
PYC Therapeutics Raises AU$40 Million via Entitlement Offer	Mar. 17	MT
Rights Issue: 1 new share @ 0.08 AUD for 4 existing shares	Mar. 17	FA
PYC Therapeutics to Raise Up to AU$75 Million for Advancing Drug Candidates	Mar. 14	MT
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	Feb. 16	MT
Transcript : PYC Therapeutics Limited - Special Call	Feb. 01
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	Jan. 01	MT
Transcript : PYC Therapeutics Limited - Shareholder/Analyst Call	Nov. 23
Transcript : PYC Therapeutics Limited - Special Call	Nov. 16
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	Nov. 13	CI
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial	Nov. 03	MT
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug	23-10-05	MT
Transcript : PYC Therapeutics Limited - Special Call	23-10-04
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance	23-09-22	MT
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	23-08-11	CI
PYC Therapeutics Raises Vision Pharma Shareholding to 96.2%	23-08-09	MT
PYC Therapeutics' RP11 Investigational Drug Candidate Secures Fast Track Designation from US FDA; Shares Climb 3%	23-08-01	MT
PYC Therapeutics Completes Toxicology Testing of Retinitis Pigmentosa Medication	23-07-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Summary

Filters